000028 国药一致
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)4.2259.5369.5769.25710.439
总资产报酬率 ROA (%)1.5023.5473.4823.2453.808
投入资产回报率 ROIC (%)2.2685.3315.3054.8915.746

边际利润分析
销售毛利率 (%)10.96411.99312.15411.73011.832
营业利润率 (%)2.5113.2693.1402.8563.628
息税前利润/营业总收入 (%)2.8543.5483.4053.2003.817
净利润/营业总收入 (%)2.0382.5952.4122.2352.886

收益指标分析
经营活动净收益/利润总额(%)79.54088.96892.31493.07384.918
价值变动净收益/利润总额(%)20.1688.9717.26914.80513.163
营业外收支净额/利润总额(%)0.9510.2350.2161.136-0.306

偿债能力分析
流动比率 (X)1.4421.4941.5081.4231.445
速动比率 (X)1.1391.1661.1351.0831.134
资产负债率 (%)58.46955.90254.37257.87657.346
带息债务/全部投入资本 (%)39.83238.61734.71338.64338.377
股东权益/带息债务 (%)133.201140.732166.172137.493136.863
股东权益/负债合计 (%)59.15565.48669.59560.27561.430
利息保障倍数 (X)8.95713.09213.19510.29418.999

营运能力分析
应收账款周转天数 (天)96.74976.13672.86378.37673.971
存货周转天数 (天)43.79342.88343.12641.48538.841